Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.34 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.31 |
| ▸ | GLP1R | P43220 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14775049 | 0.83 | ALDH1A1 (0.35) | ALDH1A1PDCD1CD274MAPKAPK2 | |
| SCHEMBL23801332 | 0.80 | SMN1; SMN2 (0.33) | ALDH1A1GLP1RHTT | |
| SCHEMBL16248171 | 0.78 | ALDH1A1 (0.35) | ALDH1A1MAPKAPK2 | |
| SCHEMBL27427582 | 0.77 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL23890508 | 0.77 | PPARA (0.32) | — | |
| SCHEMBL22167611 | 0.75 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL4306425 | 0.74 | ALDH1A1 (0.32) | ALDH1A1PDCD1CD274MAPKAPK2 | |
| SCHEMBL14775276 | 0.70 | — | — | |
| SCHEMBL6027802 | 0.69 | — | — | |
| SCHEMBL20104911 | 0.69 | PDCD1 (0.31) | PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389007-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2022-12-08 | — | — | US | disclosed |
| US-8754226-B2 | Piperidinyl-substituted lactams as GPR119 modulators | ARRAY BIOPHARMA INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20130158009-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | ARRAY BIOPHARMA, INC. | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389007-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2E, POLR2H | ALDH1A1 2912/4885PDCD1 3409/4885CD274 4261/4885 |
| US-20130158009-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | GPR119, GPR139, GPR39 | ALDH1A1 2163/4885PDCD1 4737/4885CD274 4136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.